# Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

> **NCT01975142** · PHASE2 · COMPLETED · sponsor: **Institut Curie** · enrollment: 155 (actual)

## Conditions studied

- Metastatic Breast Cancer, HER2 Negative Primary Tumor

## Interventions

- **DRUG:** Trastuzumab - Emtansine

## Key facts

- **NCT ID:** NCT01975142
- **Lead sponsor:** Institut Curie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-07
- **Primary completion:** 2018-02-13
- **Final completion:** 2019-01-21
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01975142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01975142, "Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01975142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*